Waterfront Wealth Inc. Has $1.06 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Waterfront Wealth Inc. boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,633 shares of the specialty pharmaceutical company’s stock after buying an additional 103 shares during the period. Waterfront Wealth Inc.’s holdings in Jazz Pharmaceuticals were worth $1,062,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. International Assets Investment Management LLC bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $7,201,000. DekaBank Deutsche Girozentrale boosted its holdings in Jazz Pharmaceuticals by 94.2% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock worth $11,210,000 after purchasing an additional 44,414 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in Jazz Pharmaceuticals by 558.6% during the third quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock worth $41,780,000 after purchasing an additional 273,764 shares during the last quarter. AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 40.8% in the third quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company’s stock valued at $23,184,000 after acquiring an additional 51,871 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC boosted its stake in Jazz Pharmaceuticals by 242.8% in the third quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock valued at $35,023,000 after acquiring an additional 191,648 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:JAZZ traded down $1.80 during midday trading on Wednesday, reaching $107.10. 592,713 shares of the company’s stock were exchanged, compared to its average volume of 614,110. The firm’s 50 day simple moving average is $120.35 and its two-hundred day simple moving average is $122.69. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 17.50, a P/E/G ratio of 1.53 and a beta of 0.59. Jazz Pharmaceuticals plc has a fifty-two week low of $106.61 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. As a group, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. Corporate insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group decreased their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a report on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, March 22nd. Truist Financial restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Stifel Nicolaus raised their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a report on Friday, March 15th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.